Author

Ryan Kern

Georgia Institute of Technology

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adegboyega K. OyelereiD· 2 shared Alexis JohnstoniD· 2 shared Bocheng WuiD· 2 shared Dipak T. WalunjiD· 2 shared Jeremiah Olorunjuwon OlugbamiiD· 2 shared Nathaniel A. HathawayiD· 2 shared Travis J. NelsoniD· 2 shared Arvind Bangaru· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adegboyega K. OyelereORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual-acting Estrogen Receptor Modulator-Histone Lysine Demethylase Inhibitors

Dipak T. Walunj, Jeremiah Olorunjuwon Olugbami, Bocheng Wu, Ryan Kern, Alexis Johnston, Sonia Batan, Jabunnesa Khanom, Femi A. Egbeleke, Travis J. Nelson, Verjine Khodaverdian, Veronica Ventura, Nathaniel A. Hathaway, Muthusamy Thangaraju, Adegboyega K. Oyelere

This paper develops dual-acting inhibitors combining estrogen receptor ligands with KDM inhibitors, showing potent anti-proliferative effects against both ER+ and ER- breast cancer cells in xenograft models.

bioRxiv · May 29, 2026 · PreprintCancer Biology

Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone.

Alexis Johnston, Jeremiah Olorunjuwon Olugbami, Dipak T. Walunj, Arvind Bangaru, Bocheng Wu, Ryan Kern, Ruiqiao Yang, Travis J. Nelson, Brandon J. Clarke, Janani Murugan, Nathaniel A. Hathaway, Yuhong Fan, Adegboyega K. Oyelere

This study identifies KDM inhibition as a key anticancer mechanism of DFP and demonstrates PROTACs as a strategy to enhance its therapeutic potential.

ACS Omega · Apr 28, 2026Peer-reviewedCancer Biology